Drug news
NICE confirms recommendation for Xofigo (radium-223) for treatment of prostate cancer- Bayer Health Care
The National Institute for Health and Care Excellence has now recommended Xofigo (radium-223) from Bayer HealthCare for men who have already been treated with chemotherapy docetaxel for prostate cancer, as long as Bayer provides Xofigo (radium-223) at an undisclosed discount through a patient access scheme. A 6-month course of the product, which uses targeted radiation to kill tumor cells to penetrate the bone, is costed at around �24,240 ($36,928).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.